Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTPRZ1 | P23471 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23588314 | 0.88 | PDE2A (0.37) | PDE2AMEN1KMT2AHTTLMNA | |
| SCHEMBL25254226 | 0.88 | MEN1 (0.34) | PDE2AMEN1KMT2AHTTLMNA | |
| SCHEMBL23578311 | 0.87 | MEN1 (0.35) | PDE2AMEN1KMT2AHTTLMNA | |
| SCHEMBL25223995 | 0.86 | S1PR1 (0.36) | PDE2AMEN1KMT2AHTTMAPT | |
| SCHEMBL30304210 | 0.85 | PDE2A (0.36) | PDE2AMEN1KMT2AHTTLMNA | |
| SCHEMBL27022955 | 0.84 | KMT2A (0.46) | MEN1KMT2AHTTLMNAALOX5AP | |
| SCHEMBL25214650 | 0.84 | KMT2A (0.36) | MEN1KMT2AHTTLMNAALOX5AP | |
| SCHEMBL30304246 | 0.81 | PDE2A (0.36) | PDE2AMEN1KMT2AHTTPTPRZ1 | |
| SCHEMBL24802372 | 0.80 | PDE2A (0.34) | PDE2AMEN1KMT2AHTTLMNA | |
| SCHEMBL24801177 | 0.77 | PDE2A (0.34) | PDE2AMEN1KMT2AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459908-B2 | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | claimed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | claimed |
| EP-4192821-A1 | ALPHA,BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | Sitryx Therapeutics Limited (GB) | 2023-06-14 | — | — | EP | claimed |
| US-12459908-B2 | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | SITRYX THERAPEUTICS LIMITED (GB) | 2025-11-04 | — | — | US | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2024-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459908-B2 | Alpha, beta unsaturated methacrylic esters with anti-inflammatory properties | PTGS1, PTGER1, PTGES2 | PDE2A 772/4885MEN1 2557/4885KMT2A 3983/4885 |
| US-20240018111-A1 | ALPHA, BETA UNSATURATED METHACRYLIC ESTERS WITH ANTI-INFLAMMATORY PROPERTIES | PTGS1, PTGER1, PTGES2 | PDE2A 772/4885MEN1 2557/4885KMT2A 3983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.